FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies
Early Prediction of Clinical Response to Chemotherapy With FLT-PET
Sponsor: M.D. Anderson Cancer Center
This PHASE1 trial investigates Malignant Neoplasm and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 13 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed · Phase: NA → PHASE1
-
Jan 2023 — Jul 2023 [monthly]
Active Not Recruiting NA
-
Jul 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
▶ Show 8 earlier versions
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting NA
-
Jun 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting NA
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Jul 2017 — Jan 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .